The Middle East Health Journal
SEE OTHER BRANDS

Catch up with healthcare and wellness news from the Middle East

The Middle East Health Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.

Press releases published on May 23, 2025

Résultats des Votes de l’Assemblée Générale Mixte des Actionnaires Réunies le 22 mai 2025

Résultats des Votes de l’Assemblée Générale Mixte des Actionnaires Réunies le 22 mai 2025

Daix (France), New York City (New York, Etats-Unis), le 23 mai 2025 – Inventiva (Euronext Paris et NASDAQ : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la …

OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPα Blockade in Two Ongoing Trials at ASCO 2025

OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPα Blockade in Two Ongoing Trials at ASCO 2025

OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPα Blockade in Two Ongoing Trials at ASCO 2025 BI 765063 in combination with programmed …

OSE Immunotherapeutics annonce que son partenaire Boehringer Ingelheim présentera des premières données cliniques issues de deux essais en cours

OSE Immunotherapeutics annonce que son partenaire Boehringer Ingelheim présentera des premières données cliniques issues de deux essais en cours

OSE Immunotherapeutics annonce que son partenaire Boehringer Ingelheim présentera des premières données cliniques issues de deux essais en cours sur la modulation de l’immunité innée et l’activité antitumorale via le blocage de SIRPα à l’ASCO 2025 BI …

Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock

Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock

SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced the pricing of its previously announced underwritten public offering of …

Algernon Closes NoBrainer Imaging Centers, Inc. Acquisition

Algernon Closes NoBrainer Imaging Centers, Inc. Acquisition

VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinical stage drug development company, is pleased to announce …

Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025

Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025

ROCKVILLE, Md. and SUZHOU, China, May 22, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, today announced that new clinical data from two …

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new data from several studies of compounds discovered by HUTCHMED including savolitinib, …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service